initial public offerings (IPOs) trading on American exchanges

Wednesday, April 15, 2015

Aduro BioTech (ADRO) began trading on the NASDAQ on 15 April 2015




Description


Aduro BioTech Inc is a United States-based clinical-stage immunotherapy company. The Company has developed or acquired technology platforms designed to activate potent and lasting immune responses against cancer: live, attenuated Listeria, GVAX and cyclic dinucleotides (CDNs). Aduro’s lead program is an immunotherapy regimen combining Listeria-based CRS-207 and GVAX Pancreas in patients with metastatic pancreatic cancer who have failed at least one therapy. Its pipeline includes CRS-207, ADU-623, ADU-214, ADU-741, CDN and STINGVAX. CRS-207 is based on Aduro’s Listeria platform. ADU-623 is Aduro's first clinical bivalent Listeria-based immunotherapy. ADU-214 is a bivalent Listeria-based immunotherapy that targets both mesothelin and an EGFR mutation. CDNs are small molecules that signal through STING and induce a potent immune response. STINGVAX is the combination of CDNs and GVAX.

Address

626 Bancroft Way Ste 3-C
BERKELEY, CA 94710-2224
United States

Key stats and ratios

Q4 (Dec '14)2014
Net profit margin-9.30%-127.07%
Operating margin-11.38%-142.79%
EBITD margin--141.00%
Return on average assets-4.39%-24.96%
Return on average equity-7.19%-47.17%
Employees50

No comments:

Post a Comment